Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia

John Lauriello, Joseph P. McEvoy, Stephen Rodriguez, Cynthia A. Bossie, Robert A. Lasser

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Maintenance treatment regimens for patients with schizophrenia are often suboptimal. Partial adherence and outright noncompliance are associated with symptom recurrence and increased likelihood of rehospitalization. Long-acting conventional neuroleptics have limited efficacy and are associated with treatment-limiting adverse events, while oral atypical antipsychotics have not improved adherence substantially. A long-acting formulation of risperidone, an atypical antipsychotic with proven efficacy, has been developed. Introduction of long-acting injectable treatment may be appropriate during inpatient hospitalization, when consequences of relapse are most evident. To support this intervention, a subanalysis of patients who were inpatients at study initiation was conducted from a 12-week, double-blind, placebo-controlled long-acting risperidone study (N=214). Long-acting risperidone was associated with a significant reduction in total Positive and Negative Syndrome Scale (PANSS) score (mean change±standard error [S.E.] at endpoint: long-acting risperidone, -9.27±1.44, n=133; placebo, 0.72±2.59, n=41; P<0.001), and a significantly higher rate of treatment response, defined as ≥20% reduction in total PANSS score (50% vs. 27%, P<0.05). Significantly more long-acting risperidone patients had endpoint Clinical Global Impressions (CGI) assessments of not ill, very mild or mild (32% vs. 5%; P<0.01). Long-acting risperidone was well tolerated. Long-acting risperidone initiated during inpatient treatment may be an important strategy in improving long-term outcomes among patients with schizophrenia.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalSchizophrenia Research
Issue number2-3
StatePublished - Jan 1 2005
Externally publishedYes


  • Adherence
  • Depot
  • Long-acting antipsychotic
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia'. Together they form a unique fingerprint.

Cite this